BBMG Corporation (02009) announced its annual performance, with a net loss attributable to the owners of the company of 1.009 billion yuan, an increase of 81.83% year-on-year.
China Gezhouba Group Corporation (02009) announced its annual performance as of December 31, 2025. The group achieved operating income of RMB 91.113 billion (the same unit below), a decrease of 17.7% year-on-year; net loss attributable to the owners of the parent company was RMB 1.009 billion, an increase of 81.83% year-on-year; basic loss per share attributable to the parent company's shareholders (excluding other equity instruments interest) was approximately RMB 0.19; proposed final dividend of RMB 0.05 per share.
BBMG Corporation (02009) released its annual performance as of December 31, 2025. The Group achieved operating income of RMB 91.113 billion, a decrease of 17.7% year-on-year; the net loss attributable to the owners of the parent company was RMB 1.009 billion, an increase of 81.83% year-on-year; the basic loss per share attributable to the owners of the parent company (excluding other equity instruments interest) was approximately RMB 0.19; it is proposed to distribute a final dividend of RMB 0.05 per share.
During the reporting period, the main operating income of the new green building materials sector was approximately RMB 79.58 billion, an increase of approximately 1.7% year-on-year, and the gross profit of the main operating business of the new green building materials sector was approximately RMB 8.064 billion, an increase of approximately 11.9% year-on-year. During the reporting period, cement and clinker sales were approximately 83.45 million tons (excluding about 5.17 million tons from the company's joint ventures), a decrease of approximately 1.1% year-on-year. Among them, cement sales were approximately 73.32 million tons (excluding about 4.63 million tons from joint ventures), a decrease of approximately 2.8% compared to the same period last year, and clinker sales were approximately 10.13 million tons (excluding about 0.54 million tons from joint ventures), an increase of approximately 13.4% compared to the same period last year. The comprehensive gross profit margin of cement and clinker was approximately 20.9%, an increase of approximately 5.0 percentage points year-on-year. The concrete business achieved sales of approximately 15.69 million cubic meters, an increase of approximately 20.3% year-on-year, with a selling price of RMB 279.3 per cubic meter, a decrease of approximately RMB 25.5 per cubic meter year-on-year, and a gross profit margin of approximately 10.7%, an increase of approximately 2.2 percentage points year-on-year.
During the reporting period, the main operating income of the real estate development and operation sector was approximately RMB 11.498 billion, a decrease of approximately 64.9% year-on-year, and the gross profit of the main operating business of the real estate development and operation sector was approximately RMB 2.638 billion, a decrease of approximately 36.4% year-on-year. The turnover area was 531,800 square meters, a decrease of approximately 51.8% year-on-year, with commercial housing turnover area of 426,000 square meters, a decrease of approximately 56.5% year-on-year, and policy housing turnover area of approximately 105,800 square meters, a decrease of approximately 14.9% year-on-year. The cumulative contracted amount was approximately RMB 10.912 billion, a decrease of approximately 19.0% year-on-year, and the cumulative contracted area was approximately 507,700 square meters, a decrease of approximately 24.5% year-on-year. As of the end of the reporting period, the company had a total land reserve equity area of 5.4637 million square meters.
Related Articles

CHINA RE (01508) released its annual performance, with a net profit attributable to shareholders of 9.771 billion yuan, a decrease of 7.44% year-on-year.

OCUMENSION-B(01477): The first patient has been enrolled in the Phase III clinical trial of OT-211.

CHANGMAO BIO (00954) announced a net loss attributable to shareholders of approximately 66.763 million yuan in 2025, a year-on-year decrease of 2.17%.
CHINA RE (01508) released its annual performance, with a net profit attributable to shareholders of 9.771 billion yuan, a decrease of 7.44% year-on-year.

OCUMENSION-B(01477): The first patient has been enrolled in the Phase III clinical trial of OT-211.

CHANGMAO BIO (00954) announced a net loss attributable to shareholders of approximately 66.763 million yuan in 2025, a year-on-year decrease of 2.17%.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


